Drug | Mechanism of action | Phase of development | Stage of disease |
---|---|---|---|
Solanezumab | Aβ – Passive Immunization | III | PRE, MD |
Crenezumab | Aβ – Passive Immunization | II | PRE, MD |
BIIB-037 | Aβ – Passive Immunization | III | PRO, MD |
ACI-Anti-Tau Ab | Tau – Passive Immunization | I | MMD |
MK-8931 | BACE Inhibition | II/III | PRO, MD |
ACC-001 | Aβ – Active Immunization | II | MMD |
ACI-24 | Aβ – Active Immunization | II | MMD |
CAD-106 | Aβ – Active Immunization | II | MMD |
ACI-35 | Tau – Active Immunization | I | MMD |
ACI-24 | Tau – Active Immunization | II | MMD |
NGF | Neuroprotectant | II | MMD |
TTP-488 | RAGE Inhibitor | III | MMD |
EVP-6124 | Cholinergic agonist | II | MMD |
AZD0530 | Fyn kinase inhibitor | II | MD |
Pioglitazone | PPAR-γ agonist | III | PRE |